Skip to main content
. 2020 Jan 24;112(9):921–928. doi: 10.1093/jnci/djaa008

Figure 1.

Figure 1.

Recurrence-free survival (RFS) probability of stage I–III melanoma patients using American Joint Committee on Cancer Staging Manual Seventh Edition (AJCC7) and Eighth Edition (AJCC8). A) Stage IA and IB melanoma patients using AJCC7. B) Stage IIA, IIB, and IIC melanoma patients using AJCC7. C) Stage IIIA, IIIB, and IIIC melanoma patients using AJCC7. D) Stage IA and IB melanoma patients using AJCC8. E) Stage IIA, IIB, and IIC melanoma patients using AJCC8. F) Stage IIIA, IIIB, IIIC, and IIID melanoma patients using AJCC8. The Kaplan-Meier curves were generated for each substage with data from patients enrolled in the Interdisciplinary Melanoma Cooperative Group database at NYU Langone Health. The curves were compared, and P values were calculated using a two-sided log-rank test. The 5-year RFS probabilities with corresponding 95% confidence intervals for each substage are reported for both staging systems in the tables on the right.